Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

UBT251

UBT251 Injection Phase Ⅲ Study (Overweight or Obesity)

The United Bio-Technology (Hengqin) Co · Phase 3 · Active, not recruiting · Enrollment 600

NCT07648225

Participants reaching a weight loss threshold

Participants reaching threshold, %

Source: Cited trial source. The denominator is the source figure, when it states one.

No selected arm reports a responder percent.

Show as table
Arm≥5%≥10%≥15%≥20%
UBT251 Injection 4.0 mgn/rn/rn/rn/r
UBT251 Injection 6.0 mgn/rn/rn/rn/r
UBT251 Injection Placebo 4.0 mgn/rn/rn/rn/r
UBT251 Injection Placebo 6.0 mgn/rn/rn/rn/r

Not shown

  • UBT251 Injection 4.0 mg: endpoint not reported
  • UBT251 Injection 6.0 mg: endpoint not reported
  • UBT251 Injection Placebo 4.0 mg: endpoint not reported
  • UBT251 Injection Placebo 6.0 mg: endpoint not reported